WMT · 10-Q · 2026Q2 · Full report

Regulatory Investigations and Litigation

Walmart Inc. · 2026-05-29 · Importance 40 · Surprise 42

The filing discloses multiple ongoing regulatory investigations and litigation matters referenced in the Condensed Consolidated Financial Statements (Note 5) and Legal Proceedings, including opioid-related litigation (Prescription Opiate Litigation, DOJ opioid civil litigation and False Claims Act matters), Asda Equal Value Claims (indemnification obligation), a U.S. Attorney's Office investigation into Money Transfer Agent Services (consumer fraud prevention and AML compliance), Driver Platform matters (FTC and state Attorneys General litigation), a Mexico antitrust matter (COFECE process and constitutional challenge by Walmex), Indian regulatory matters (FDI show cause notice to Flipkart and an India antitrust matter), and an environmental matter with the U.S. EPA. The Company states these matters are contingent liabilities that may or may not result in material liability upon final resolution and provides related disclosure in the Legal Proceedings note.

Key facts

• The Company disclosed multiple ongoing legal matters including Opioid-Related Litigation, Asda Equal Value Claims, Money Transfer Agent Services Matter, Driver Platform Matters, Mexico Antitrust Matter, and India Antitrust Matter as contingent liabilities. source